AMPD1: A novel therapeutic target for reversing insulin resistance

BMC Endocrine Disorders

Volumn 14, Issue 1, 2014, Pages

  Cheng, Jidong ^a,d   Morisaki, Hiroko ^a   Toyama, Keiko ^a,b   Sugimoto, Naomi ^a,b   Shintani, Takuya ^a,b   Tandelilin, Andreas ^a   Hirase, Tetsuaki ^a   Holmes, Edward W ^c   Morisaki, Takayuki ^a,b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Sanford Consortium for Regenerative Medicine   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Adenine nucleotide; AMP deaminase; AMP kinase; Diabetes; Glucose metabolism; Insulin resistance

Indexed keywords

ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CYCLIC AMP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOSINE PHOSPHATE; ADENOSINE MONOPHOSPHATE DEAMINASE; AMPD1 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL;

AMPD1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CELL LEVEL; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE; GENE DISRUPTION; GENE EXPRESSION; GENE TARGETING; GLUCOSE TOLERANCE TEST; HOMOZYGOTE; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; MUSCLE METABOLISM; NONHUMAN; OBESITY; SKELETAL MUSCLE; ANIMAL; C57BL MOUSE; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; TRANSGENIC MOUSE;

AMP DEAMINASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SKELETAL; OBESITY;

EID: 84964313124     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-14-96     Document Type: Article

References (16)

1. International Diabetes Federation: IDF Diabetes Atlas, 6th edn. Brussels: International Diabetes Federation; 2013 [http://www.idf.org/sites/default/ files/EN_6E_Atlas_Full_0.pdf]
2. Kahn SE, Cooper ME, Prato SD: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014, 383:1068-1083.
3. Turner N, Cooney GJ, Kraegen EW, Bruce CR: Fatty acid metabolism, energy expenditure and insulin resistance in muscle. J Endocrinol 2014, 220:T61-T79.
4. Ouyang J, Parakhia RA, Ochs RS: Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011, 286:1-11.
5. Hardie DG: AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013, 62:2164-2172.
6. Norman B, Sabina RL: Myoadenylate deaminase deficiency. In The Online Metabolic & Molecular Bases of Inherited Disease. Edited by Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A. New York: McGraw-Hill; 2010. doi:10.1036/ommbid.138.
7. Cheng J, Morisaki H, Sugimoto N, Dohi A, Shintani T, Kimura E, Toyama K, Ikawa M, Okabe M, Higuchi I, Matsuo S, Kawai Y, Hisatome I, Sugama T, Holmes EW, Morisaki T: Effect of isolated AMP deaminase deficiency on skeletal muscle function. Mol Genet Metab Rep 2014, 1:51-59.
8. Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, Richey JM, Ader M: Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 2007, 120:S3-S8.
9. Goodarzi MO, Taylor KD, Guo X, Quiñones MJ, Cui J, Li X, Hang T, Yang H, Holmes E, Hsueh WA, Olefsky J, Rotter JI: Variation in the gene for muscle-specific AMP deaminase is associated with insulin clearance, a highly heritable trait. Diabetes 2005, 54:1222-1227.
10. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365:1333-1346.
11. Buettner R, Schölmerich J, Bollheimer LC: High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity 2007, 15:798-808.
12. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
13. Admyre T, Amrot-Fors L, Andersson M, Bauer M, Bjursell M, Drmota T, Hallén S, Hartleib-Geschwindner J, Lindmark B, Liu J, Löfgren L, Rohman M, Selmi N, Wallenius K: Inhibition of AMP deaminase activity does not improve glucose control in rodent models of insulin resistance or diabetes. Chem Biol 2014, 21:1486-1496.
14. Plaideau C, Lai Y-C, Kviklyte S, Zanou N, Löfgren L, Andersén H, Vertommen D, Gailly P, Hue L, Bohlooly-Y M, Hallén S, Rider MH: Effects of pharmacological AMP deaminase inhibition and Ampd1 deletion on nucleotide levels and AMPK activation in contracting skeletal muscle. Chem Biol 2014, 21:1497-1510.
15. Safranow K, Czyzycka E, Binczak-Kuleta A, Rzeuski R, Skowronek J, Wojtarowicz A, Jakubowska K, Olszewska M, Loniewska B, Kaliszczak R, Kornacewicz-Jach Z, Ciechanowicz A, Chlubek D: Association of C34T AMPD1 gene polymorphism with features of metabolic syndrome in patients with coronary artery disease or heart failure. Scand J Clin Lab Invest 2009, 69:102-112.
16. Safranow K, Suchy J, Jakubowska K, Olszewska M, Binczak-Kuleta A, Kurzawski G, Rzeuski R, Czyzycka E, Loniewska B, Kornacewicz-Jach Z, Ciechanowicz A, Chlubek D: AMPD1 gene mutations are associated with obesity and diabetes in Polish patients with cardiovascular diseases. J Appl Genet 2011, 52:67-76.